Payment overview · 2025
General Payments
$377.91
16 reported records · 9 companies
Healthcare provider profile · identity verified
Basil Colin Hamblin, MD
Allopathic & Osteopathic Physicians|Hospitalist · POINT REYES STATION, CA · NPI 1114095106
Verified facts
What the public records show
CMS Open Payments records show Basil Colin Hamblin, MD received $377.91 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Lokelma, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.39 | 17.6% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.89 | 14.3% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $48.11 | 12.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $47.18 | 12.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $46.47 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.61 | 8.9% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $32.44 | 8.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.83 | 7.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.99 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.91 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $48.11 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $48.11 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $46.47 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $33.61 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 241 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
241 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 82 |
| Lisinopril | Lisinopril | 350 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 63 |
| Eliquis | Apixaban | 241 | 40 |
| Gabapentin | Gabapentin | 214 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 57 |
| Trazodone Hcl | Trazodone Hcl | 187 | 48 |
| Losartan Potassium | Losartan Potassium | 175 | 50 |
| Metformin Hcl | Metformin Hcl | 173 | 47 |
| Furosemide | Furosemide | 159 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Omeprazole | Omeprazole | 87 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 29 |
| Finasteride | Finasteride | 83 | 23 |
| Mirtazapine | Mirtazapine | 79 | 20 |
| Atenolol | Atenolol | 75 | 22 |
| Cephalexin | Cephalexin | 74 | 31 |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 24 |
| Xarelto | Rivaroxaban | 68 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 36 |
| Memantine Hcl | Memantine Hcl | 67 | 15 |
| Levetiracetam | Levetiracetam | 65 | 14 |
| Sertraline Hcl | Sertraline Hcl | 65 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 13 |
| Jardiance | Empagliflozin | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Lorazepam | Lorazepam | 63 | 36 |
| Potassium Chloride | Potassium Chloride | 62 | 14 |
| Baclofen | Baclofen | 60 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Lovastatin | Lovastatin | 58 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 24 |
| Spironolactone | Spironolactone | 56 | 11 |
| Allopurinol | Allopurinol | 55 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Carvedilol | Carvedilol | 52 | 18 |
| Prednisone | Prednisone | 50 | 25 |
| Glipizide | Glipizide | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 18 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Acyclovir | Acyclovir | 40 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 33 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Naloxone Hcl | Naloxone Hcl | 33 | 21 |
| Risperidone | Risperidone | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 16 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 11 |
| Famotidine | Famotidine | 25 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 15 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | 14 |
| Rytary | Carbidopa/Levodopa | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.91 · 16 records | PFIZER INC. | Arikayce, Belbuca, CRYSVITA, ELIQUIS, INGREZZA, JARDIANCE, LOKELMA, NURTEC ODT, PAXLOVID, VYVGART, VYVGART HYTRULO, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error